Company news

X4 Pharmaceuticals, Inc. news in 2023

X4 Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

December 8, 2023

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

November 8, 2023

X4 Pharmaceuticals to Report Third-Quarter 2023 Financial Results and Host a Conference Call and Webcast on November 9, 2023

November 1, 2023

X4 Pharmaceuticals Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome

October 30, 2023

X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

October 17, 2023

X4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM Syndrome

September 4, 2023

X4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program

August 9, 2023

X4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical Officer

August 7, 2023

X4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules Capital

August 2, 2023

X4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023

August 1, 2023

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

May 15, 2023

X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market

May 15, 2023

X4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate Update

May 3, 2023

X4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023

April 25, 2023

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)

April 11, 2023

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 20, 2023

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023

March 6, 2023

Calls in 2023

Decks in 2023